CRSP
CRISPR Therapeutics AG
Key Financials
Revenue
$3.5M
↓ 90.6%
Net Income
$-581599000
↓ 58.8%
Operating Income
$-664571000
↓ 42.4%
EPS (Diluted)
$-6.47
↓ 49.1%
Total Assets
$2.3B
↑ 1.0%
Cash & Equivalents
$347.6M
↑ 16.5%
Shareholders' Equity
$1.9B
↓ 0.5%
Total Liabilities
$343.4M
↑ 10.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CRSP |
| Company Name | CRISPR Therapeutics AG |
| CIK | 1674416 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | V8 |
| Phone | 6173154600 |